Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenyleneiodonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 16/20 | 0.68 |
| ▸ | CYBB | P04839 | 2/20 | 0.64 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.64 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.64 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenyleneiodonium SCHEMBL2057393 | 0.91 | GPR3 (0.73) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL219548 | 0.80 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL29486373 | 0.80 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL10834144 | 0.77 | GPR3 (0.93) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL30150802 | 0.77 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL159318 | 0.77 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL5547280 | 0.75 | GPR3 (0.94) | GPR3CYBBNOX5NOX4NOX1 | |
| Sulfuric Acid SCHEMBL3380495 | 0.68 | MAPT (0.59) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| Naphthoquinone SCHEMBL29148131 | 0.67 | CDC25B (0.61) | MEN1KMT2ATSHRSMN1; SMN2NPC1 | |
| Sulfuric Acid SCHEMBL2057392 | 0.66 | MAPT (0.56) | MEN1KMT2ATSHRSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0784471-B1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | HIV DIAGNOSTICS INC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| US-20100278751-A1 | RADIOLABELED 2-AMINO-4-ALKYL-6-(HALOALKYL)PYRIDINE COMPOUNDS AND THEIR USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-11-04 | — | — | US | disclosed |
| EP-0784471-B1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | HIV DIAGNOSTICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6514955-B1 | An agent in an amount effective to cause blood glutathione levels to increase, antioxidants at a dose higher than the recommended daily minimum requirement; and nuclear factor kappa B (NFKB) induction inhibitor | HIV DIAGNOSTICS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-5846961-A | Multi-faceted method to repress reproduction of latent viruses in humans and animals | HIV DIAGNOSTICS, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | disclosed |
| US-5686436-A | SUPPRESSING HUMAN IMMUNODEFICIENCY VIRUS, FELINE IMMUNODEFICIENCY VIRUS, FELINE LEUKEMIA VIRUS | HIV DIAGNOSTICS, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278751-A1 | RADIOLABELED 2-AMINO-4-ALKYL-6-(HALOALKYL)PYRIDINE COMPOUNDS AND THEIR USE IN DIAGNOSTIC IMAGING | NOS2, NOS3, NOS1 | GPR3 842/4885CYBB 146/4885NOX5 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.